Recommendations on the use of everolimus in lung transplantation.

Autores de IIS La Fe

• Amparo Solé Jover

  Autor

• Jose Maria Borro Mate

  Autor

• Manuel Cifrian Perez

  Autor

Participantes ajenos a IIS La Fe

• de Pablo A
• Santos F
• Laporta R
• Monforte V
• Román A
• de la Torre M
• Ussetti P
• Zurbano F

Grupos

• Infección Grave

Abstract

The antiproliferative effect of everolimus provides a therapeutic option in the immunosuppression therapy of lung transplantation, by reducing both the risk of acute rejection and the process of progressive fibrosis that determines chronic graft rejection. However, few data on the use of everolimus in lung transplantation have been published to date, and the specific indications of the drug, along with the most adequate time for its introduction or dosing, have not been defined yet. The aim of this article is to propose recommendations for the use of everolimus in lung transplant recipients, including indications, dosing schedules and the use of concomitant immunosuppression. This consensus document has been developed by experts of all the Spanish lung transplant groups from the review of the existing literature and the clinical experience.